Steven Lichtman
Stock Analyst at Oppenheimer
(4.17)
# 483
Out of 4,667 analysts
67
Total ratings
48.48%
Success rate
17.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $75.24 | +39.55% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $109.27 | +23.55% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $6.88 | +74.42% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $85.50 | +28.65% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $84.20 | +11.64% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $44.81 | +45.06% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $30.15 | +92.37% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $9.83 | +11.90% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $6.74 | +78.04% | 2 | Apr 5, 2024 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $82 → $87 | $104.08 | -16.41% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $90.49 | -24.85% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $2.06 | +69.90% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $300 → $275 | $266.58 | +3.16% | 5 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $385.68 | -25.33% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $141.44 | -25.76% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $26.32 | +469.91% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $99.08 | -14.21% | 3 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.75 | - | 2 | Apr 12, 2017 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $75.24
Upside: +39.55%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $109.27
Upside: +23.55%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $6.88
Upside: +74.42%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $85.50
Upside: +28.65%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $84.20
Upside: +11.64%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $44.81
Upside: +45.06%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $30.15
Upside: +92.37%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $9.83
Upside: +11.90%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.74
Upside: +78.04%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $104.08
Upside: -16.41%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $90.49
Upside: -24.85%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $2.06
Upside: +69.90%
Jan 31, 2022
Upgrades: Outperform
Price Target: $300 → $275
Current: $266.58
Upside: +3.16%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $385.68
Upside: -25.33%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $141.44
Upside: -25.76%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $26.32
Upside: +469.91%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $99.08
Upside: -14.21%
Apr 12, 2017
Downgrades: Perform
Price Target: n/a
Current: $0.75
Upside: -